Yabao Pharmaceutical: ZY-A002 receives Approval Notice for Drug Clinical Trials.

Yabao Pharmaceutical Announcement: Recently received the "Drug Clinical Trial Approval Notice" for ZY-A002 approved and issued by the National Medical Products Administration. The indications for ZY-A002 are dispelling wind and promoting lung qi, relieving spasms and coughs, mainly used for children with cough-variant asthma, symptoms include paroxysmal coughing, itchy throat leading to coughing, little or no phlegm, or clear nasal discharge, pale tongue with thin white coating, and string-like pulse.